Jane Street’s Climb Bio CLYM Stock Holding History

Jane Street’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,600	Closed	-$100K	–	13494
2026 Q1	$100K	Buy	+14,600	New	+$84.2K	﹤0.01%	10657

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street's CLYM Position: Q2 2026 in Review

Jane Street reduced its Climb Bio (CLYM) stake by 23% in Q2 2026, selling an estimated $409K and leaving 131,761 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #5453.

Jane Street first reported a position in CLYM in Q3 2024 and has held it in 6 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

Jane Street held 131,761 shares of Climb Bio worth $1.72M as of Q2 2026.
Jane Street sold 39,614 Climb Bio shares in Q2 2026, an estimated $409K.
Climb Bio made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #5453 holding.
Jane Street first reported a position in Climb Bio in Q3 2024 and has held it in 6 quarters since.
108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.